Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Area Under Curve
Carboplatin
/ administration & dosage
Cetuximab
/ administration & dosage
Cisplatin
/ administration & dosage
Drug Interactions
Female
Fluorouracil
/ administration & dosage
Humans
Male
Middle Aged
Neoplasms
/ blood
carboplatin
cetuximab
cisplatin
pharmacokinetics
solid tumor
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
19
09
2018
revised:
07
06
2019
accepted:
13
06
2019
entrez:
3
12
2019
pubmed:
4
12
2019
medline:
7
7
2020
Statut:
epublish
Résumé
The pharmacokinetics and potential drug-drug interactions between cetuximab and cisplatin or carboplatin from two studies (JXBA and JXBB) were evaluated. These studies were multicenter, open-label phase II trials designed to evaluate the drug-drug interactions between cetuximab (400 mg m
Identifiants
pubmed: 31788317
doi: 10.1002/prp2.519
pii: PRP2519
pmc: PMC6875703
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Cetuximab
PQX0D8J21J
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00519Subventions
Organisme : NCI NIH HHS
ID : P30 CA023108
Pays : United States
Informations de copyright
© 2019 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Déclaration de conflit d'intérêts
This study was supported by Eli Lilly and Company, Indianapolis, Indiana, USA. Raymond Perez has received research funding from Eli Lilly and company, Bristol‐Meyers Squibb, Dompe Farmaceutici, Novartis, Millennium, Agensys, Immunogen, TetraLogic Pharmaceuticals, Altor BioScience, Incyte, Onyx, MedImmune, Genentech and Regeneron. Eric Chen, J. Thaddeus Beck, Keisuke Shirai and David Neil Hayes have no conflict of interest related to this study. Shuang He and Steve Chin are employed at Eli Lilly and own equity. Katherine Bryant retired from Eli Lilly and company in December 2017.
Références
J Clin Oncol. 2005 Dec 1;23(34):8646-54
pubmed: 16314626
J Clin Oncol. 2006 Jun 10;24(17):2666-72
pubmed: 16763281
J Clin Oncol. 2007 Jun 1;25(16):2171-7
pubmed: 17538161
J Clin Oncol. 2005 Aug 20;23(24):5578-87
pubmed: 16009949
Gene. 2006 Jan 17;366(1):2-16
pubmed: 16377102
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
J Clin Oncol. 2006 Jun 20;24(18):2866-72
pubmed: 16717293
Ann Oncol. 2008 Feb;19(2):362-9
pubmed: 17947225
Cancer Treat Rev. 2014 Apr;40(3):390-404
pubmed: 24176789
J Clin Oncol. 2005 Aug 20;23(24):5568-77
pubmed: 16009950
Pharmacol Res Perspect. 2019 Nov 25;7(6):e00519
pubmed: 31788317